Skip to main content

Advertisement

Figure 3 | BMC Psychiatry

Figure 3

From: Quetiapine fumarate augmentation for patients with a primary anxiety disorder or a mood disorder: a pilot study

Figure 3

During 8 weeks of quetiapine XR augmentation to antidepressant treatment among patients with a primary anxiety disorder or a mood disorder with comorbid anxiety symptoms, a statistically significant difference was observed between the quetiapine XR group and the placebo group at Week 4 compared to baseline on the CGI-S score (p = 0.025). However, no statistically significant difference was observed between the two groupsat Week 8 compared to baseline on the CGI-S score. CGI-S: Clinical Global Impression–severity of illness.

Back to article page